A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
Condition: Hodgkin's Lymphoma
MeSH terms: Lymphoma; Hodgkin Disease
Intervention: Panobinostat; Placebo
Intervention description: Placebo
Intervention MeSH terms: Panobinostat
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 41.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Phase III randomized; double blind; placebo controlled multi-center study; panobinostat; Hodgkin's lymphoma; at risk for relapse; autologous stem cell transplant

Summary:

      The primary objective was to provide drug to ongoing patients who were receiving panobinostat
      and to characterize the safety and tolerability of panobinostat in patients with HL after
      achieving a complete response following autologous hematopoietic stem cell transplant (AHSCT)
      with high dose chemotherapy (HDT). Primary objective as stated above reflects a change from
      the original protocol as of an amendment. The original objective was no longer feasible with
      only 41 of 367 patients randomized after the study was halted due to poor recruitment. An
      amendment was written to allow patients on panobinostat to continue their treatment until
      discontinuation/completion criteria were met (patients were unblinded). Therefore, the study
      was completed as per this amendment. No secondary objectives were included for this trial
      from the amendment; this was a change from the original protocol.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patient age is greater than or equal to 18 years

          2. Patient has a history of histologically confirmed classical HL (i.e. Nodular
             sclerosing (NSHL), Mixed-cellularity (MCHL), Lymphocyte-rich (LRHL), Lymphocyte
             depleted (LDHL))

          3. Patient has achieved a complete response by CT/MRI scan within 9 weeks (± 1 week) from
             the day of their first autologous peripheral blood/ bone marrow stem cell transfusion
             (AHSCT) following HDT. Complete response is defined as:

             Normalization of all nodes and lesions compared to pre-transplant scan performed prior
             to salvage therapy for relapse. Any residual abnormal masses on the post transplant
             CT/MRI must be metabolically inactive on a PET scan.

          4. Patient has at least one of the following factors that places them at risk for
             relapse:

               -  Primary refractory disease (including relapse in ≤ 3 months of completion of 1st
                  line treatment)

               -  First relapse >3 but <12 months from last dose of 1st line treatment

               -  Multiple relapses (prior to transplant)

               -  Stage III/IV disease (at relapse, prior to transplant)

               -  Hemoglobin <10.5 gm/dL (at relapse, prior to transplant)

        Exclusion Criteria:

        Patient has been treated with allogeneic transplant 2. Patient has received any
        anti-lymphoma therapy after AHSCT including but not limited to:

          -  chemotherapy prior to start of study

          -  biologic immunotherapy including monoclonal antibodies or experimental therapy prior
             to start of study

          -  radiation therapy 3. Patient has not recovered from reversible toxicity due to any
             prior therapies (e.g. returned to baseline or Grade ≤1) except for hematological
             laboratory parameters Note: Patient does not meet this criteria if the toxicity is
             stable and irreversible, and there is no evidence that panobinostat causes a similar
             toxicity 4. Patient has received prior treatment with DAC inhibitors including
             panobinostat